While PET imaging is the fastest-growing segment of the Radiopharmaceutical Market, Single Photon Emission Computed Tomography (SPECT) imaging remains a stable and significant one. SPECT scans, which use a gamma-emitting radiopharmaceutical to visualize a patient's organ function, are a critical tool in the diagnosis of a wide range of conditions, particularly in cardiology and neurology. The lower cost and greater accessibility of SPECT scanners, when compared to PET scanners, ensure their continued use in a wide range of healthcare settings. The Radio Pharmaceutical Market report provides a detailed breakdown of the market by imaging modality, highlighting the continued importance of this segment.

The market for SPECT-based radiopharmaceuticals is seeing a major focus on developing new drugs that can be used to diagnose a wider range of conditions. The future of the Radiopharmaceutical Market will be defined by the continued coexistence of these two market segments, as each fills a specific and critical need in the healthcare system.